Summary
- Current Price
- As of today, ARWR price is $43.65, up +1.25% on
- Current Price All-Time High
- ARWR price is currently -98.51% below its historical high of $2,925.00 set on
- Market Cap
- ARWR current market cap is $6B, up +16.69% over the past 365 days
- Revenue
- ARWR current annual revenue is $450.82M, down -45.65% year-over-year
- Next Earnings
- The next earnings release for ARWR is on
Profile
| Metric | Value |
|---|---|
| Full Name | Arrowhead Pharmaceuticals, Inc. |
| Ticker | NASDAQ: ARWR |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | arrowheadpharma.com |
| Employees | 609 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $43.65 | |
| Price, 1D Change | +1.25% | |
| Market Cap | $6B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.41 | |
| Revenue | $450.82M | |
| Revenue, 1Y Change | -45.65% | |
| EPS | -$5.11 | |
| EPS, 1Y Change | -41,812.30% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:10 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | -$5.11 | |
| EPS Estimate | -$5.34 | N/A |
| EPS Est. Change | -4.39% | N/A |
| Revenue | $450.82M | |
| Revenue Estimate | $320.81M | N/A |
| Revenue Est. Change | -28.84% | N/A |
| Current Price | $43.65 | |
| Price Target | $105.50 | - |
| Price Tgt. Change | +141.70% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$0.03 | -$0.01 | +63.69% | |
| -$3.51 | -$5.11 | -45.54% | |
| -$5.34 | N/A | -4.39% | |
| -$3.22 | N/A | +37.00% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $757.44M | $829.45M | +9.51% | |
| $464.14M | $450.82M | -2.87% | |
| $320.81M | N/A | -28.84% | |
| $674.34M | N/A | +49.58% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +12.01% | |
| Price, 3Y | +55.56% | |
| Market Cap, 1Y | +16.69% | |
| Market Cap, 3Y | +104.93% | |
| Revenue, 1Y | -45.65% | |
| Revenue, 3Y | +87.27% | |
| EPS, 1Y | -41,812.30% | |
| EPS, 3Y | -165.90% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $43.65 | |
| SMA 200 | $70.54 | |
| SMA 50 | $60.07 | |
| EMA 200 | $65.49 | |
| EMA 50 | $59.69 | |
| MACD | -$5.11 | |
| Beta | 1.41 | |
| ATR | $2.91 | |
| 14-Day RSI | 23.36 | |
| 10-Day Volatility | 85.05% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $450.82M | |
| EPS | -$5.11 | |
| Gross Profit | $422.57M | |
| Gross Margin | 93.73% | |
| Operating Income | -$707.17M | |
| Operating Margin | -156.86% | |
| Net Income | -$717.13M | |
| Net Margin | -159.07% | |
| EBITDA | -$680.55M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 27.84 | |
| 4.14 | ||
| 4.11 | ||
| - | ||
| 1 | ||
| -0.11 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | - | |
| 13.69 | ||
| 122.65 | ||
| -9.37 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $50.31M | |
| $1.19B | ||
| $1.81B | ||
| $1.29B | ||
| $1.76B | ||
| $311.34M | ||
| Total Debt | $1.40B | |
| $45.50M | ||
| $30.15M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $1.18B | ||
| $1.13B | ||
| $28.25M | ||
| $202.05M | ||
| $26.62M | ||
| $0.00 | ||
| -$6.78M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| -$271.95M | ||
| -$670.48M | ||
| $776.82M | ||
| Capex | $12.00M | |
| -$283.94M |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Stifel | → | |
| RBC Capital | → | |
| HC Wainwright & Co. | → | |
| Chardan Capital | → | |
| Citigroup | ||
| HC Wainwright & Co. | → | |
| RBC Capital | → | |
| Chardan Capital | → | |
| HC Wainwright & Co. | → | |
| B. Riley Securities | → |
Analyst sentiment
Institutional ownership
No data
Screeners with ARWR
FAQ
- What is the ticker symbol for Arrowhead Pharmaceuticals, Inc.?
- The ticker symbol for Arrowhead Pharmaceuticals, Inc. is NASDAQ:ARWR
- Does Arrowhead Pharmaceuticals, Inc. pay dividends?
- No, Arrowhead Pharmaceuticals, Inc. does not pay dividends
- What sector is Arrowhead Pharmaceuticals, Inc. in?
- Arrowhead Pharmaceuticals, Inc. is in the Healthcare sector
- What industry is Arrowhead Pharmaceuticals, Inc. in?
- Arrowhead Pharmaceuticals, Inc. is in the Biotechnology industry
- What country is Arrowhead Pharmaceuticals, Inc. based in?
- Arrowhead Pharmaceuticals, Inc. is headquartered in United States
- When did Arrowhead Pharmaceuticals, Inc. go public?
- Arrowhead Pharmaceuticals, Inc. initial public offering (IPO) was on December 16, 1993
- Is Arrowhead Pharmaceuticals, Inc. in the S&P 500?
- No, Arrowhead Pharmaceuticals, Inc. is not included in the S&P 500 index
- Is Arrowhead Pharmaceuticals, Inc. in the NASDAQ 100?
- No, Arrowhead Pharmaceuticals, Inc. is not included in the NASDAQ 100 index
- Is Arrowhead Pharmaceuticals, Inc. in the Dow Jones?
- No, Arrowhead Pharmaceuticals, Inc. is not included in the Dow Jones index
- When was Arrowhead Pharmaceuticals, Inc. last earnings report?
- Arrowhead Pharmaceuticals, Inc.'s most recent earnings report was on November 12, 2026
- When does Arrowhead Pharmaceuticals, Inc. report earnings?
- The next expected earnings date for Arrowhead Pharmaceuticals, Inc. is February 4, 2027
Data Sources & References
- ARWR Official Website arrowheadpharma.com
- ARWR Profile on Yahoo Finance finance.yahoo.com/quote/ARWR
- ARWR Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/arwr
